Breast cancer drug approvals issued by EMA: A review of clinical trials

Gianluca Franceschini, Giorgia Garganese, Giovanni Scambia, Gennaro Daniele, Antonella Palazzo, Ida Paris

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.
Lingua originaleEnglish
pagine (da-a)1-17
Numero di pagine17
RivistaCancers
Volume13
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Breast cancer
  • EMA
  • Drugs approval

Fingerprint

Entra nei temi di ricerca di 'Breast cancer drug approvals issued by EMA: A review of clinical trials'. Insieme formano una fingerprint unica.

Cita questo